VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
AORT
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
AORTArtivion, Inc.
$18.27$887M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
AORT logo

Artivion, Inc.

AORT
NYSE · Medical Devices
$18.27
At close - Nov 17, 4:00 PM EST - USD
Market Cap$887M
P/E-50.6x
52W High$48.25
Volume561.74K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q3

Revenue Growth Undercut by Margin Compression and Cash Burn

Artivion's revenue grew from $95.8M in 2024Q3 to $123.8M in 2026Q3, yet operating margin collapsed to 2.4% from 11.1% a year earlier and net margin turned to -6.4%, suggesting top-line momentum is not converting into bottom-line delivery.

GrowthMixed
ProfitabilityStrained
ValuationExpensive
TechnicalsWeak
Explore valuation models
MARKET ACTION

AORT price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

4/12 Beats

EPS beat 4 of last 12 quarters

02

Valuation risk

-286% Peers

P/E is 286% below peer median

03

Market leadership

RS 20 · Lag

Laggard (Underperforming 80% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Feb 5

Market performance

Price History →

Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
AORT-58.91%
S&P 500 (^GSPC)+7.21%
1-Year Return
AORT-59.51%
S&P 500 (^GSPC)+10.03%
3-Year Return
AORT+33.45%
S&P 500 (^GSPC)+65.21%
5-Year Return
AORT-7.21%
S&P 500 (^GSPC)+53.93%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E5Y Low
-50.6x
Forward P/E
N/A
EV/EBITDA40th %ile
31.4x
FCF YieldCash Flow
N/A

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
-50.6x
217.2x
0th· Low
EV/EBITDA
31.4x
34.3x
40th· Fair
Price/FCF
N/A
107.8x
N/A
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
Bear$4.65-74.5%
Base (Fair)$11.71-48.1%
Bull$15.91-12.9%
$4.65 Bear$11.71 Base$15.91 Bull
Current Market Price: $18.27
Trades at a 56.0% premium to Base DCF ($11.71)
Open DCF & Valuation Models →Chart Terminal ↗

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$441M+13.6% YoY
Net income FY25
$10M+173.1% YoY
Free cash flow FY25
-$911K-108.2% YoY
Operating margin FY25
6.1%-3.9 pts YoY
ROIC (FY25)3.2%
Avg ROIC 5Y2.1%
ROE (TTM)-3.9%
Piotroski Score6 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate4/12 (33%)
Revenue Beat Rate10/12 (83%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 5, 2026
$0.08+230.6%
vs -$0.06
$124M+2.3%
vs $121M
Q3 2026
Aug 6, 2026
-$0.28-11300.0%
vs $0.00
$126M+4.8%
vs $120M
Q2 2026
May 7, 2026
$0.03-50.0%
vs $0.06
$116M+0.6%
vs $116M
Q1 2026
Feb 12, 2026
$0.05-63.6%
vs $0.14
$116M-0.4%
vs $116M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
MarketBeat·Nov 6, 2026
Artivion Q3 Earnings Call Highlights

Artivion NYSE: AORT reported 9% constant-currency revenue growth in the third quarter of 2026, while adjusted earnings declined as the medical device maker invested in manufacturing and prepared for the U.S. launch of its NEXUS aortic repair system.

Seeking Alpha·Nov 5, 2026
Artivion, Inc. (AORT) Q3 2026 Earnings Call Transcript

Artivion, Inc. (AORT) Q3 2026 Earnings Call Transcript

Zacks Investment Research·Nov 5, 2026
Artivion (AORT) Lags Q3 Earnings Estimates

Artivion (AORT) came out with quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.16 per share a year ago.

PRNewsWire·Nov 5, 2026
Artivion Reports Third Quarter 2026 Financial Results

Third Quarter & Recent Business Highlights: Achieved revenue of $123.8 million in the third quarter of 2026 versus $113.4 million in the third quarter of 2025, an increase of 9% on a GAAP basis and 9% on a non-GAAP constant currency basis  Net loss for the third quarter of 2026 was $(7.9) million, or $(0.16) per fully diluted share, and non-GAAP net income was $3.8 million, or $0.08 per fully diluted share Adjusted EBITDA declined 8% to $22.5 million in the third quarter of 2026 compared to $24.6 million in the third quarter of 2025 ATLANTA, Nov. 5, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the third quarter ended September 30, 2026. "In the third quarter of 2026, we delivered 9% constant currency revenue growth, reflecting continued execution of our strategy to drive long-term, profitable growth through an expanding and clinically differentiated product portfolio.

Filtered for Artivion, Inc.More Headlines
04

Compare before deciding

Benchmark AORT against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Artivion, Inc. (AORT)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
AORT logoAORTArtivion, Inc.Current
$18.27$886.89M-50.6013.59%-3.65%-3.93%—
NVCR logoNVCRNovocure Ltd
$11.14$1.29B-10.698.28%-16.78%-35.81%—
ATRC logoATRCAtriCure, Inc.
$55.02$2.8B184.2014.88%2.52%2.93%—
NNOX logoNNOXNano-X Imaging Ltd.
$0.29$20.01M-0.1715.4%-747.19%-94.35%—
TMDX logoTMDXTransMedics Group, Inc.
$93.91$3.25B26.5537.13%19.85%28.38%—
GMED logoGMEDGlobus Medical, Inc.
$69.99$9.44B17.0716.65%17.76%11.82%—

Compare AORT vs Peers

Artivion, Inc. (AORT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs NVCR

Most directly comparable listed peer for AORT.

Scale Benchmark

vs ABT

Larger-name benchmark to compare AORT against a more recognizable public peer.

Peer Set

Compare Top 5

vs NVCR, ATRC, NNOX, TMDX

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

AORT SEC Filings & Documents

Artivion, Inc. (AORT) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Nov 5, 2026·SEC

Material company update

Aug 6, 2026·SEC

Material company update

May 18, 2026·SEC

10-K Annual Reports

2
FY 2026

Feb 18, 2026·SEC

FY 2025

Feb 28, 2025·SEC

10-Q Quarterly Reports

6
FY 2026

Nov 6, 2026·SEC

FY 2026

Aug 7, 2026·SEC

FY 2026

May 8, 2026·SEC

Get notified when AORT posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

AORT Frequently Asked Questions

Artivion, Inc. (AORT) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Artivion, Inc.'s revenue?

Artivion, Inc. (AORT) reported $481.9M in revenue over the trailing twelve months. Revenue was $441.3M in fiscal year 2025. That is 1093% more than the $37.0M of fiscal year 1996.

How fast is Artivion, Inc. growing?

Artivion, Inc. (AORT) grew revenue by 14.0% over the trailing twelve months, compared with the twelve months before.

Is AORT profitable?

No. Artivion, Inc. (AORT) reported a net loss of $17.6M over the trailing twelve months.

Dividend & Returns
What is AORT's return on equity?

Artivion, Inc. (AORT) had a return on equity (ROE) of -3.9% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is Artivion, Inc.'s free cash flow?

Artivion, Inc. (AORT) had negative free cash flow of $44.4M over the trailing twelve months.

What if you invested $1,000 in AORT back in 1996?

Total return calculator · dividends reinvested · 30+ years of data

See returns →